Research Topics
Species | Kristie A BlumSummaryAffiliation: The Ohio State University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Adult Burkitt leukemia and lymphomaKristie A Blum
Division of Hematology and Oncology, The Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, A437 Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
Blood 104:3009-20. 2004....- 90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphomaKristie A Blum
The Ohio State University, Division of Hematology and Oncology, Arthur G James Cancer Hospital, Columbus 43210 1240, USA
Expert Opin Biol Ther 4:1323-31. 2004..Toxicities are primarily neutropenia and thrombocytopenia, with few infectious complications. 90Yttrium-ibritumomab tiuxetan is an effective therapeutic alternative for the treatment of NHL... - Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphomaMehdi Hamadani
Department of Hematology and Oncology and Bone Marrow Transplantation, The Ohio State University, Columbus, Ohio 43210, USA
Leuk Lymphoma 49:1893-8. 2008..Day 100 and overall non-relapse mortality rate was 12.5% and 25%, respectively. Allogeneic HSCT appears feasible in patients with transformed FL and is associated with acceptable treatment-related mortality and low relapse rates... 
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridolEmilia Mahoney
Division of Hematology, Department of Internal Medicine, College of Pharmacy, The Ohio State University OSU, Columbus, OH 43210, USA
Blood 120:1262-73. 2012....- Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk diseaseThomas S Lin
Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
J Clin Oncol 27:6012-8. 2009..Given the relevance of these findings to treating genetically high-risk CLL, a prospective confirmatory study was initiated... - Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasmaQing Liu
Division of Pharmaceutics, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, USA
Ther Drug Monit 30:620-7. 2008..This sensitivity will enable late terminal phase concentration measurements and accurate pharmacokinetic parameter estimation in a planned clinical trial with lenalidomide and flavopiridol in patients with chronic lymphocytic leukemia... - Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disordersThomas S Lin
Division of Hematology and Oncology, The Ohio State University, Center for Biostatistics, The Ohio State University, Columbus, OH 43210, USA
J Clin Oncol 28:418-23. 2010..We conducted a phase I study of flavopiridol, fludarabine, and rituximab (FFR) in patients with mantle-cell lymphoma (MCL), indolent B-cell non-Hodgkin's lymphomas (B-NHL), and CLL to determine the activity of FFR... - Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Sarah E M Herman
Integrated Biomedical Science Graduate Program, The Ohio State University Medical Center, Columbus, OH, USA
Blood 117:6287-96. 2011..Based on these collective data, future efforts targeting BTK with the irreversible inhibitor PCI-32765 in clinical trials of CLL patients is warranted... - Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphomaLapo Alinari
Department of Internal Medicine, Division of Hematology and Oncology, Ohio State University, Columbus, Ohio 43210, USA
MAbs 1:31-40. 2009.... - Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemiaMitch A Phelps
Comprehensive Cancer Center, College of Pharmacy, Division of Pharmaceutics, The Ohio State University, Columbus, OH 43210, USA
Blood 113:2637-45. 2009..These composite results confirm high activity of this pharmacokinetically derived schedule in relapsed, genetically high-risk CLL. Furthermore, PK describes some, but not all, variability in response and toxicity... - High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphomaMehdi Hamadani
Department of Internal Medicine, Division of Hematology Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
Eur J Haematol 81:425-31. 2008..At a median follow-up of 38 months, 3-yr progression-free survival following autologous HSCT was 40%. The 3-yr overall survival was 52%. The cumulative incidence of relapse and non-relapse mortality rate was 41% and 25%, respectively... - Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylationKristie A Blum
Division of Hematology Oncology, Department of Internal Medicine, The Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
Br J Haematol 150:189-95. 2010..In conclusion, dose-limiting myelosuppression and infectious complications prevented dose escalation of decitabine to levels associated with changes in global methylation or gene re-expression in CLL and NHL... - Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomasMehdi Hamadani
Hematology and Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
Biol Blood Marrow Transplant 15:547-53. 2009..Given the outcomes seen here in the setting of PD, such patients should proceed with transplant only in the setting of investigational therapy... - FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell deathLapo Alinari
Division of Hematology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, USA
Blood 118:6893-903. 2011..Significant in vivo therapeutic activity of combination treatment was also demonstrated in a preclinical, in vivo model of MCL. These findings support clinical evaluation of this combination in patients with MCL... - The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemiaSarah E M Herman
Integrated Biomedical Science Graduate Program, The Ohio State University Medical Center, Columbus, OH 43210, USA
Blood 117:4323-7. 2011.... - Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphomaKristie A Blum
Division of Hematology Oncology, Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
Leuk Lymphoma 50:349-56. 2009..Clofarabine exhibits evidence of single agent activity in relapsed or refractory DLBCL. However, further study with novel administration schedules that maintain this efficacy and limit toxicity is warranted... - The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivoDavid M Lucas
Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
PLoS ONE 5:e10941. 2010..We therefore investigated the novel DAC inhibitor AR-42 to determine its efficacy in B-cell malignancies... - Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive diseaseJennifer A Woyach
The Ohio State University, Columbus, USA
Br J Haematol 148:754-9. 2010..2;p11.2) is a novel recurrent cytogenetic abnormality in CLL associated with early age at diagnosis and accelerated disease progression. Future efforts to identify genes disrupted by this translocation are warranted and ongoing... - Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donorBeth Christian
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
J Clin Oncol 28:e629-32. 2010 - Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathwayRosa Lapalombella
Division of Hematology and Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
Blood 115:2619-29. 2010..This study is registered at http://clinicaltrials.gov as NCT00466895... - Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemiaKristie A Blum
Division of Hematology Oncology, Ohio State University Medical Center, Columbus, OH 43210, USA
Br J Haematol 147:507-14. 2009..Future investigations in CLL should focus on broad HDAC inhibition, combination strategies, and approaches to diminish constitutional symptoms associated with this class of drugs... - Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206Kristie A Blum
Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
Leuk Lymphoma 48:1313-9. 2007..Grade 3 - 4 adverse events, primarily thrombocytopenia, occurred in 15 patients. Therefore, although well tolerated, 1.3 mg/m(2) bortezomib administered biweekly has no single agent activity in relapsed/refractory classical HL... - Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphomaLapo Alinari
Division of Hematology, Department of Medicine, College of Medicine, The Ohio State University, Columbus, USA
Blood 117:4530-41. 2011..Significant in vivo therapeutic activity of combination rituximab and milatuzumab was demonstrated in a preclinical model of MCL. These data support clinical evaluation of combination milatuzumab and rituximab therapy in MCL... - Evaluation and management of lymphoma and leukemia in pregnancyJonathon B Cohen
Department of Internal Medicine, Division of Hematology, The Arthur G James Comprehensive Cancer Center and The Ohio State University, Columbus, Ohio, USA
Clin Obstet Gynecol 54:556-66. 2011..Many women are able to be treated successfully and deliver healthy babies... - Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153Kristie A Blum
Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio 43210, USA
Cancer 107:2817-25. 2006..The objective of this study was to determine the efficacy and toxicity of 2-chlorodeoxyadenosine (2-CdA) in patients with untreated, indolent non-Hodgkin lymphoma (NHL)... - Upcoming diagnostic and therapeutic developments in classical Hodgkin's lymphomaKristie A Blum
Division of Hematology, The Arthur G James Comprehensive Cancer Center and The Ohio State University, Columbus, OH 43210, USA
Hematology Am Soc Hematol Educ Program 2010:93-100. 2010..This review examines current data using the IPS to determine patient outcome, discuss several potential biologic prognostic markers, and summarize new therapies that are currently in clinical development in HL... - Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteriaKristie A Blum
The Ohio State University, Division of Hematology Oncology, Starling Loving Hall, Room B324, Columbus, OH 43210, USA
J Clin Oncol 25:5624-9. 2007..The widespread use of computed tomography (CT) scans has prompted many to advocate for the incorporation of this test into CLL response criteria... - Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasmaJeffrey S Johnston
Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
J Chromatogr B Analyt Technol Biomed Life Sci 871:15-21. 2008..It is the first analytical method reported to date for the quantitation of both 17AAG and its metabolite 17AG and can reliably quantitate concentrations of both compounds as low as 0.5 ng/mL... - Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphomaAmy L Hoerr
School of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO, USA
J Clin Oncol 22:4561-6. 2004.... - Antibodies for the treatment of diffuse large cell lymphomaKristie A Blum
Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO, USA
Semin Oncol 30:448-56. 2003..These agents may be most promising when combined with either chemotherapy or with rituximab. This review will summarize the use of rituximab in the therapy of diffuse large B-cell lymphoma and briefly describe antibodies in development... - Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignanciesPaula M Fracasso
Alvin J Siteman Cancer Center, St Louis, Missouri, USA
Cancer 95:2223-9. 2002..We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancies...